Drug intelligence / Profile preview

AcuVera

Development stage: Preclinical
Lead developer: CuRsuS Bio
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Transdermal

Overview

AcuVera is a transdermal microneedle patch system developed by CuRsuS Bio for cosmetic and dermatological applications, including the treatment of acne, fine lines, wrinkles, and dark circles. The patches utilize the proprietary MicroLock™ technology, which features dissolvable, biodegradable microneedles designed to penetrate the stratum corneum and deliver active ingredients directly into the skin. This delivery mechanism is intended to provide higher efficacy than traditional topical formulations by ensuring deeper penetration of the therapeutic or cosmetic agents. The AcuVera line is currently in the preclinical stage of development and is primarily positioned for the skincare market.

Brand names: AcuVera
Other names: AcuVera PatchMicroLock microneedle patch

Beyond the preview

Go deeper on AcuVera.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AcuVera.

Explore the full profile